Feedback / Questions
Ibrance (palbociclib) - Pfizer
Ibrance: Data from P3 PALLAS trial (NCT02513394) for HR+/HER2- breast cancer in early 2021
(Pfizer)
-
Jan 28, 2020 -
Q4 2019 Results
P3 data
https://s21.q4cdn.com/317678438/files/doc_financials/2019/q4/Q4-2019-Earnings-Charts-FINAL.pdf
Jan 28, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious